Last reviewed · How we verify

Fluticasone Propionate_3

Imperial College London · FDA-approved active Small molecule

Fluticasone propionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in target tissues.

Fluticasone propionate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in target tissues. Used for Asthma (maintenance therapy), Chronic obstructive pulmonary disease (COPD), Allergic rhinitis.

At a glance

Generic nameFluticasone Propionate_3
SponsorImperial College London
Drug classCorticosteroid (glucocorticoid)
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaRespiratory / Dermatology / Immunology
PhaseFDA-approved

Mechanism of action

Fluticasone propionate is a synthetic glucocorticoid that exerts anti-inflammatory effects by binding to intracellular glucocorticoid receptors, leading to suppression of pro-inflammatory cytokine production, reduction of immune cell infiltration, and decreased vascular permeability. It is commonly used in inhaled or topical formulations to reduce inflammation in respiratory and dermatological conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: